Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMK36 (fluciclovine 18F) single-dose IV in clinically suspected glioma
jRCT2080222933Phase 3Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Aug 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluciclovine f 18 in glioma (2 arms), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoint: 9-month progression-free survival (%9mo-PFS) in suspected high-grade glioma group. Started Aug 2015; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2080222933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222933.